110 related articles for article (PubMed ID: 3095944)
1. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.
Verstraete M; Bounameaux H; de Cock F; Van de Werf F; Collen D
J Pharmacol Exp Ther; 1985 Nov; 235(2):506-12. PubMed ID: 4057083
[TBL] [Abstract][Full Text] [Related]
3. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H
Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
[TBL] [Abstract][Full Text] [Related]
5. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
6. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
8. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
9. The effect of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat.
Bloom JC; Sellers TS; Gries GC; Wheeldon EB; O'Brien SR; Lewis HB
Thromb Haemost; 1988 Oct; 60(2):271-9. PubMed ID: 3146143
[TBL] [Abstract][Full Text] [Related]
10. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
11. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.
Seifried E; Tanswell P; Rijken DC; Barrett-Bergshoeff MM; Su CA; Kluft C
Arzneimittelforschung; 1988 Mar; 38(3):418-22. PubMed ID: 3132929
[TBL] [Abstract][Full Text] [Related]
13. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
16. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
Klein P; Roth FJ; Rieger H; Popov-Cenic S
Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
[TBL] [Abstract][Full Text] [Related]
17. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
[TBL] [Abstract][Full Text] [Related]
18. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
19. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
20. [Local low dosage thrombolysis with rt-PA. Systemic effects on the fibrinolytic system--data on the assessment of the value and risk of this method].
von Bilderling P; Spannagl M; Mietaschk A; Iven M; Schramm W; Hess H
Vasa Suppl; 1991; 33():132-3. PubMed ID: 1788645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
